Endologix (Endologix) Construction In Progress : $0.7 Mil (As of Jun. 2020)

View and export this data going back to 1996. Start your Free Trial

What is Endologix Construction In Progress?

Endologix's quarterly construction in progress declined from Dec. 2019 ($0.8 Mil) to Mar. 2020 ($0.7 Mil) and declined from Mar. 2020 ($0.7 Mil) to Jun. 2020 ($0.7 Mil).

Endologix's annual construction in progress increased from Dec. 2017 ($0.7 Mil) to Dec. 2018 ($1.0 Mil) but then declined from Dec. 2018 ($1.0 Mil) to Dec. 2019 ($0.8 Mil).

Endologix Construction In Progress Historical Data

The historical data trend for Endologix's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endologix Construction In Progress Chart

Endologix Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Construction In Progress

Get a 7-Day Free Trial

0.51

0.84

0.74

0.99

0.80

Endologix Quarterly Data
	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20
Construction In Progress	Get a 7-Day Free Trial															0.98	0.79	0.80	0.69	0.68

Endologix Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Endologix (Endologix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Endologix Inc (OTCPK:ELGXQ) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Musick, Irvine, CA, USA, 92618

Website

http://www.endologix.com

Endologix Inc develops, manufacture, market, and sell innovative medical devices for the treatment of aortic disorders in the United States and internationally. The company only reporting segment that is focused on the development, manufacture, marketing, and sale of EVAR and EVAS products for the treatment of aortic disorders. It product Includes a variety of endovascular stent grafts for the treatment of abdominal aortic aneurysms such as AFX Endovascular AAA System, VELA Proximal Endograft, and Ovation Abdominal Stent Graft System. The firm generates the majority of its revenue in the United States.

Executives

Dan Lemaitre	director	2 MUSICK, IRVINE CA 92618
Gregory D Waller	director	1717 W COLLINS AVENUE, ORANGE CA 92867
John Onopchenko	director, officer: CEO and Director	C/O VOLCANO CORPORATION 11455 EL CAMINO REAL, SUITE 460 SAN DIEGO CA 92130
Thomas Wilder	director	2 MUSICK, IRVINE CA 92618
Matthew Thompson	officer: Chief Medical Officer	2 MUSICK, IRVINE CA 92618
Timothy Nicholas Brady	officer: Controller and Corp Secretary	2 MUSICK IRVINE CA 92618
Cynthia Buch Pinto	officer: Interim CFO	2 MUSICK IRVINE CA 92618
Jeff Fecho	officer: Chief Quality Officer	ONE ST. JUDE MEDICAL DRIVE ST. PAUL MN 55117
Richard W Mott	director	1221 CROSSMAN AVENUE, SUNNYVALE CA 94089
Vaseem Mahboob	officer: Chief Financial Officer	2 MUSICK IRVINE CA 92618
Jane E Kiernan	director	525 W ROSCOE, CHICAGO IL 60657
John Zehren	officer: Chief Commercial Officer	2 MUSICK IRVINE CA 92618
Jeremy B. Hayden	officer: General Counsel	2 MUSICK, 2 MUSICK, IRVINE CA 92618
Leslie V Norwalk	director	C/O 3661 VALLEY CENTRE DRIVE SUITE 200, SAN DIEGO CA 92130
Zenty Iii Thomas F	director	2 MUSICK IRVINE CA 92618